Pulse Biosciences Clarifies Details of Recent S-3 Filing
August 24 2023 - 4:05PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today provided additional
clarification regarding the details of the SEC form S-3 (“the
filing”) filed August 11, 2023.
The only shares registered in the filing are those currently
owned by the “selling securityholder”, identified as Robert W.
Duggan, Executive Chairman of the Pulse Biosciences Board of
Directors. The shares were received in connection to the May, 2023
private placement which effectively cancelled all prior
indebtedness owned by the Company to Mr. Duggan, including the
principal balance of $65 million and accrued and unpaid interest of
approximately $250,000. No additional shares were authorized or
registered by the Company. Mr. Duggan has informed the Company that
he has no present intention to sell the shares registered in this
prospectus, or any of his Pulse Biosciences holdings.
Mr. Duggan commented, “We are encouraged by the recent business
progress and especially the preclinical study results achieved by
the nsPFA cardiac ablation catheter and surgical ablation clamp
devices. I believe there is a promising future ahead for Pulse
Biosciences as we seek to advance the treatment of atrial
fibrillation and am proud to continue my support of the Company
both as Executive Chairman of the Board and as long-term
shareholder.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including, among other
things, statements relating to the effectiveness of the Company’s
nsPFA technology and CellFX System to non-thermally clear cells
while sparing adjacent non-cellular tissue, statements concerning
the Company’s expected product development efforts, such as
advancement of its cardiac clamp through the appropriate FDA
regulatory path and possible initiation of a first-in-human safety
feasibility study of its nsPFA cardiac ablation catheter system,
statements concerning the Company’s future regulatory strategies
and possible government clearances and approvals, statements
concerning customer adoption and future use of the CellFX System to
address a range of conditions such as atrial fibrillation and
benign thyroid nodules, statements about the Company’s future
financing opportunities and operating expenses, and Pulse
Biosciences’ expectations, whether stated or implied, regarding
whether the Company’s nsPFA technology will become a disruptive
treatment option for treating cardiac arrhythmias, benign thyroid
nodules or any other medical condition and whether future clinical
studies will show the CellFX System is safe and effective to treat
atrial fibrillation, benign thyroid nodules or any other medical
condition, and other future events. In addition, statements
regarding the intentions of the Company or its affiliates as to the
issuance or sale of Company securities are inherently contingent
and subject to change. These statements are not historical facts
but rather are based on Pulse Biosciences’ current expectations,
estimates, and projections regarding Pulse Biosciences’ business,
operations and other similar or related factors. Words such as
“may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,”
“potential,” “continue,” “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” and other similar or related expressions
are used to identify these forward-looking statements, although not
all forward-looking statements contain these words. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Pulse Biosciences’ control. Actual results may differ
materially from those in the forward-looking statements as a result
of a number of factors, including those described in Pulse
Biosciences’ filings with the Securities and Exchange Commission.
Pulse Biosciences undertakes no obligation to revise or update
information in this release to reflect events or circumstances in
the future, even if new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230824305287/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com or Gilmartin
Group Philip Trip Taylor 415.937.5406 philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024